Organization

HGBEYOND MATERIALS SICENCE SL

Spanish materials science SME specializing in ocular drug delivery, ophthalmic formulations, and eye disease therapeutics within EU training networks.

Technology SMEhealthESSMENo active H2020 projectsThin data (2/5)

H2020 projects

As coordinator

Total EC funding

€14K

Unique partners

What they do

Their core work

HGBeyond Materials Science is a small Spanish private company specializing in materials science applied to pharmaceutical and ocular drug delivery. They contribute expertise in formulations, medicinal chemistry, and materials-based approaches to eye therapeutics, participating in EU-funded training networks focused on dry eye disease and posterior segment ocular conditions. Their work sits at the intersection of materials science and pharmaceutical development, supporting drug discovery pipelines for ophthalmic applications.

Core expertise

What they specialise in

Ocular drug delivery and formulationsprimary

3 projects

All three projects (3D NEONET, IT-DED3, ORBITAL) focus on drug delivery for eye therapeutics, with explicit keywords covering formulations, ocular modeling, and medical devices.

Dry eye disease drug developmentprimary

1 project

IT-DED3 was specifically dedicated to integrated training in dry eye disease drug development, covering biology, medicinal chemistry, and pharmaceutical formulation.

Materials science for medical devicessecondary

1 project

ORBITAL includes medical devices and materials science as explicit keywords, aligning with the company's core identity as a materials science firm.

Posterior segment eye disease therapeuticsemerging

1 project

ORBITAL specifically targets posterior segment disease with in vivo, ex vivo, and in vitro modeling approaches.

Oncology-related drug discoverysecondary

1 project

3D NEONET combined oncology and eye therapeutics in its drug discovery and delivery network.

Evolution & trajectory

How they've shifted over time

Early focus

Drug discovery and delivery

Recent focus

Ocular therapeutics and formulations

HGBeyond's earliest project (3D NEONET, 2017) covered a broader scope combining oncology and eye therapeutics in drug discovery. By 2018-2019, their involvement narrowed sharply toward ocular-specific work — dry eye disease, ocular surface research, posterior segment disease, and ophthalmic formulations. This trajectory suggests the company found its niche in eye-focused materials science and pharmaceutical formulation, moving away from broader oncology applications.

HGBeyond is deepening its specialization in ocular drug delivery and materials-based ophthalmic formulations, making them a focused partner for future eye therapeutics projects.

Collaboration profile

How they like to work

Role: third_party_expertReach: European15 countries collaborated

HGBeyond has never coordinated a project — they join as a partner or third party in large Marie Skłodowska-Curie training networks. With 52 consortium partners across 15 countries from just 3 projects, their network breadth comes from the large MSCA consortia rather than independent relationship-building. This is typical of a small specialist company that contributes niche expertise to established academic networks without taking on coordination overhead.

Through participation in large MSCA training networks, HGBeyond has been exposed to 52 unique partners across 15 countries. However, this broad network reflects the structure of MSCA consortia rather than independently cultivated partnerships.

Why partner with them

What sets them apart

HGBeyond brings an uncommon combination: materials science expertise applied specifically to ophthalmic drug delivery and formulations. As a Spanish SME in Santiago de Compostela, they operate near the University of Santiago de Compostela, a known hub for pharmaceutical research. For consortium builders, they offer industry-side materials and formulation know-how that complements academic pharmacology groups in eye therapeutics projects.

Notable projects

Highlights from their portfolio

ORBITAL
Covers the full spectrum of ocular research from formulations to in vivo models to patient-oriented research, and is the longest-running project (2019-2024).
IT-DED3
Highly specialized training network dedicated entirely to dry eye disease drug development — a focused therapeutic area with growing commercial interest.
3D NEONET
Their only project as a direct participant (not third party), combining oncology and eye therapeutics in a single drug discovery network.

Cross-sector capabilities

Advanced materials for biomedical applicationsPharmaceutical formulation and drug deliveryMedical device development for ophthalmology

Analysis note: Profile is based on only 3 projects with minimal direct EC funding (EUR 13,500 total). Two of three participations were as a third party, suggesting a limited or seconded role. No website available for verification. The company name contains a likely typo ('SICENCE' instead of 'SCIENCE'). The 52-partner network is inherited from large MSCA consortia, not indicative of independent networking capacity. Conclusions about specialization are directionally sound but should be treated as tentative given the thin evidence base.